Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer

  1. García-Carbonero, R.
  2. Van Cutsem, E.
  3. Rivera, F.
  4. Jassem, J.
  5. Gore, I.
  6. Tebbutt, N.
  7. Braiteh, F.
  8. Argiles, G.
  9. Wainberg, Z.A.
  10. Funke, R.
  11. Anderson, M.
  12. McCall, B.
  13. Stroh, M.
  14. Wakshull, E.
  15. Hegde, P.
  16. Ye, W.
  17. Chen, D.
  18. Chang, I.
  19. Rhee, I.
  20. Hurwitz, H.
Zeitschrift:
Oncologist

ISSN: 1549-490X,  1083-7159

Datum der Publikation: 2017

Ausgabe: 22

Nummer: 4

Art: Artikel

DOI: 10.1634/THEONCOLOGIST.2016-0133 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus